Irbesartan Accord (Irbesartan)

Irbesartan is indicated for conditions related to the renin‑angiotensin system, primarily hypertension and diabetic kidney disease.

• Hypertension: lowers elevated blood pressure, reducing cardiovascular risk.
• Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes.
• Proteinuria: decreases urinary protein excretion associated with diabetic kidney disease.

• Irbesartan selectively antagonizes angiotensin II type 1 (AT1) receptors on vascular smooth muscle, adrenal glands, and renal tubular cells. By blocking AT1 activation, it prevents angiotensin II‑mediated vasoconstriction, aldosterone release, and sodium‑water retention, producing vasodilation, reduced blood volume, and lowered systemic blood pressure while also attenuating pathological cardiac and renal remodeling.

Like other ARBs, Irbesartan may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after initial dosing.
• Headache: mild to moderate intensity.
• Hyperkalaemia: elevated blood potassium levels.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue or throat that may impair breathing.
• Acute renal failure: sudden decline in kidney function.
• Hepatic injury: signs of liver dysfunction such as jaundice.

When prescribing Irbesartan, clinicians should consider several safety measures to minimize risks.

• Monitor blood pressure: check regularly to ensure therapeutic control and avoid hypotension.
• Assess renal function: evaluate serum creatinine and eGFR before initiation and during therapy.
• Check serum potassium: periodic testing to detect hyperkalaemia.
• Use caution in hepatic impairment: dose adjustments may be required in patients with liver disease.
• Avoid in known hypersensitivity: discontinue if allergic reactions occur.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Irbesartan can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid)

• Concomitant use with aliskiren in patients with diabetes: increased risk of renal impairment, hyperkalaemia, and hypotension.
• Combined therapy with ACE inhibitors or other ARBs: may cause excessive reduction in blood pressure and renal function.

Moderate Interactions (Monitor Closely)

• Potassium‑sparing diuretics (e.g., spironolactone): may raise serum potassium levels.
• NSAIDs (e.g., ibuprofen): can diminish antihypertensive effect and worsen renal function.
• Lithium: may increase lithium concentrations, risking toxicity.